UBS Group AG Sells 861,148 Shares of Amylyx Pharmaceuticals, Inc. $AMLX

UBS Group AG lowered its holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 61.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 543,323 shares of the company’s stock after selling 861,148 shares during the quarter. UBS Group AG owned 0.49% of Amylyx Pharmaceuticals worth $6,563,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in AMLX. Commodore Capital LP bought a new stake in Amylyx Pharmaceuticals in the third quarter valued at about $55,386,000. First Light Asset Management LLC acquired a new position in Amylyx Pharmaceuticals in the third quarter valued at about $45,606,000. Adage Capital Partners GP L.L.C. boosted its position in Amylyx Pharmaceuticals by 54.5% in the second quarter. Adage Capital Partners GP L.L.C. now owns 8,800,000 shares of the company’s stock valued at $56,408,000 after buying an additional 3,102,395 shares in the last quarter. Millennium Management LLC boosted its position in Amylyx Pharmaceuticals by 418.6% in the first quarter. Millennium Management LLC now owns 3,081,853 shares of the company’s stock valued at $10,910,000 after buying an additional 2,487,617 shares in the last quarter. Finally, Paradigm Biocapital Advisors LP acquired a new position in Amylyx Pharmaceuticals in the third quarter valued at about $25,821,000. Institutional investors own 95.84% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on AMLX shares. HC Wainwright restated a “buy” rating and issued a $34.00 price target on shares of Amylyx Pharmaceuticals in a research report on Wednesday, March 25th. Bank of America boosted their price target on shares of Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the company a “buy” rating in a research report on Friday, February 20th. Wall Street Zen lowered shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Mizuho boosted their price target on shares of Amylyx Pharmaceuticals from $19.00 to $21.00 and gave the company an “outperform” rating in a research report on Tuesday, April 28th. Finally, Stifel Nicolaus started coverage on shares of Amylyx Pharmaceuticals in a research report on Tuesday, March 3rd. They issued a “buy” rating and a $21.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.00.

Amylyx Pharmaceuticals Trading Down 0.9%

Shares of AMLX stock opened at $12.74 on Wednesday. Amylyx Pharmaceuticals, Inc. has a 1 year low of $4.64 and a 1 year high of $18.60. The firm’s 50 day moving average is $15.24 and its 200-day moving average is $14.22. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of -8.49 and a beta of -0.11.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its earnings results on Thursday, May 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). On average, equities research analysts forecast that Amylyx Pharmaceuticals, Inc. will post -1.39 earnings per share for the current fiscal year.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.